Impact of tenofovir vs. entecavir treatment on progression of chronic hepatitis B: A nationwide cohort study
Open Access
- 5 July 2025
- journal article
- Published by Elsevier in JHEP Reports
- Vol. 7 (10) , 101511
Abstract
No abstract availableKeywords
Funding Information
- National Science and Technology Council (NSTC 112-2314-B-002-209-MY3)
This publication has 37 references indexed in Scilit:
- Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural historyJournal of Gastroenterology, 2024
- Tenofovir vs Entecavir Among Patients With HBV-Related HCC After ResectionJAMA Network Open, 2023
- Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosisHepatology International, 2023
- Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B VirusJAMA Network Open, 2022
- Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis BJAMA Oncology, 2019
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateHepatology International, 2015
- Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysisHepatology, 2015
- Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver diseaseHepatology, 2010
- Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡Hepatology, 2010